Assert-IQ vs LINQ II Insertable Cardiac Monitor

Direct competitors — feature-level head-to-head below. Comparability 95/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Assert-IQ

by Abbott Medical

LINQ II Insertable Cardiac Monitor

by Medtronic

AI Verdict

Assert-IQ and LINQ II are direct competitors, both offering advanced insertable cardiac monitors for long-term arrhythmia detection and management. Assert-IQ provides a longer monitoring duration of up to six years, while LINQ II highlights its AccuRhythm™ AI algorithms for enhanced accuracy, MRI compatibility, and a pediatric indication. The optimal choice may depend on specific clinical requirements for monitoring longevity, advanced AI capabilities, or patient age range.

Choose Assert-IQ if…

Choose Assert-IQ if your patient requires the absolute longest duration of continuous cardiac monitoring, up to six years, to capture rare or infrequent arrhythmias. This system is also well-suited for large health systems prioritizing proactive clinician alerts and a robust cloud-based platform for comprehensive arrhythmia detection and management.

View Assert-IQ →

Choose LINQ II Insertable Cardiac Monitor if…

Choose LINQ II if enhanced diagnostic accuracy through AI-powered algorithms and the flexibility of remote programming are critical for your patient's management. This device is particularly advantageous for patients who may require future MRI scans or for pediatric patients as young as two years old, offering broad compatibility and specialized features.

View LINQ II Insertable Cardiac Monitor →

When choosing between the Abbott Assert-IQ and Medtronic LINQ II insertable cardiac monitors, physicians should consider their specific practice needs and patient demographics. Both systems offer long-term, continuous cardiac monitoring with advanced arrhythmia detection, are HIPAA compliant, and have FDA clearance. However, their key differences lie in monitoring duration, AI focus, and remote management capabilities.

The Abbott Assert-IQ excels in providing the longest continuous monitoring duration, up to six years, making it suitable for patients requiring extended observation for suspected heart rhythm disorders. Its focus is on comprehensive arrhythmia detection and proactive clinician alerts, supported by a secure cloud-based data platform. In contrast, the Medtronic LINQ II, with up to 4.5 years of monitoring, distinguishes itself with its AccuRhythm™ AI algorithms, which are designed for enhanced accuracy in arrhythmia detection, and its remote programming capability. It also offers a MyCareLink Heart™ mobile app and a MyCareLink Relay™ home communicator option for data transmission, alongside a pediatric indication for patients aged two and above.

Therefore, a physician prioritizing the absolute longest monitoring duration and a robust, cloud-based data platform for general arrhythmia detection might lean towards the Assert-IQ. Conversely, a physician seeking enhanced AI-powered accuracy, the flexibility of remote programming, and a pediatric indication, especially within a practice that values mobile app integration for patients, would likely find the LINQ II to be a more fitting choice.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Assert-IQ	LINQ II Insertable Cardiac Monitor
Pricing	Enterprise	Enterprise
Deployment	Hybrid	Hybrid
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

LINQ II Insertable Cardiac Monitor

Tool B (LINQ II) offers a significant advantage in usability with its MyCareLink Heartu2122 mobile app for patient data transmission, providing a modern and convenient interface. Additionally, its remote programming capability enhances clinician usability by allowing adjustments without an in-person visit. Tool A (Assert-IQ) lacks a mobile app, which limits patient convenience for data logging and transmission.

Clinical Value

LINQ II Insertable Cardiac Monitor

While Tool A (Assert-IQ) boasts a longer monitoring period of up to 6 years, Tool B (LINQ II) offers distinct clinical advantages with its AccuRhythmu2122 AI algorithms for enhanced accuracy, MRI compatibility (1.5 and 3.0T), and a pediatric indication for patients aged 2+. These features broaden its applicability, improve diagnostic confidence, and enhance patient safety and management options.

Pricing & Value

Tie

Both tools are priced for enterprise customers, with pricing details not publicly disclosed and typically negotiated with healthcare systems. Neither offers a free trial. Without specific pricing information or comparative value propositions, it is not possible to determine a winner in this dimension.

Enterprise Readiness

LINQ II Insertable Cardiac Monitor

Both tools are from major medical device companies, are HIPAA compliant, FDA cleared, and support hybrid deployment. However, Tool B (LINQ II) demonstrates broader enterprise readiness with its stated target market ranging from 'Solo to large health systems' and a proven track record of over 1 million patients worldwide. This indicates wider adoption and scalability across various healthcare settings.

Innovation

LINQ II Insertable Cardiac Monitor

Tool B (LINQ II) showcases stronger innovation with its explicit mention of AccuRhythmu2122 AI algorithms for enhanced accuracy and remote programming capabilities, which allow for device adjustments without a patient visit. Its innovative PVC detection algorithm, MRI compatibility, and pediatric indication also highlight advanced engineering and expanded utility. Tool A (Assert-IQ) offers advanced algorithms but lacks the specific AI and remote programming distinctions.

Support & Docs

Tie

Both Abbott Medical and Medtronic are leading medical device manufacturers known for comprehensive support and documentation for their products. The provided structured facts do not offer specific details to differentiate their support offerings or documentation quality for these particular tools. Web searches confirm that both companies provide extensive professional resources, including manuals and technical information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Assert-IQ	LINQ II Insertable Cardiac Monitor
Name	Assert-IQ	LINQ II Insertable Cardiac Monitor
Company	Abbott Medical	Medtronic
Continuous Monitoring Duration	Up to 6 years	Up to 4.5 years
AI Algorithms	Advanced arrhythmia detection algorithms	AccuRhythmu2122 AI algorithms for enhanced accuracy
Remote Monitoring/Programming	Remote monitoring capabilities	Remote programming capability
Mobile App	none	both (MyCareLink Heartu2122 mobile app for data transmission)
Target Size	Large health systems, hospitals, cardiology clinics	Solo to large health systems
Data Export	yes	yes

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and LINQ II Insertable Cardiac Monitor.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the maximum monitoring durations for the Assert-IQ and LINQ II ICM systems?

The Assert-IQ system offers continuous cardiac monitoring for up to 6 years, with options for 3-year or 6-year battery life. The LINQ II system provides up to 4.5 years of continuous monitoring, though its lifespan can be reduced to 2.5 years if smartphone app optimization is continuously on.

How do both devices utilize AI for arrhythmia detection and data management?

Both devices leverage AI. Assert-IQ is powered by AI with advanced algorithms to reduce false positives for AF and Pause episodes while maintaining high sensitivity, potentially saving clinics significant time. LINQ II features AccuRhythmu2122 AI algorithms for enhanced accuracy, applying deep learning to data flowing into the CareLinku2122 network.

What are the patient data transmission methods and mobile app support for each system?

Assert-IQ uses Bluetoothu00ae Low Energy for data transmission and supports the myMerlinu2122 Mobile App for automatic check-ins and patient-initiated event logging. LINQ II offers the MyCareLink Heartu2122 mobile app for data transmission and a MyCareLink Relayu2122 home communicator option.

Are both Assert-IQ and LINQ II ICMs MRI compatible?

Yes, both devices are MRI compatible. The Medtronic LINQ II is MR Conditional at u2264 3T with no post-insertion waiting required. Assert-IQ is also conditionally safe for use in 1.5T and 3T MRI environments when used according to instructions.

Do these ICMs offer remote programming capabilities for device settings?

Yes, both systems offer remote programming. Assert-IQ ICM provides simple and secure remote programming, allowing clinicians to adjust device settings without requiring patient clinic visits. The Medtronic LINQ II also enables remote programming capability for all device parameters post-insertion.

Is either device specifically indicated for pediatric patients?

The Medtronic LINQ II system has a 510(k) clearance for use in pediatric patients aged 2 and older. Assert-IQ has not been specifically tested for pediatric use.

Do either of these ICMs highlight specific advanced arrhythmia detection algorithms beyond general AI?

Yes, both mention specific algorithms. LINQ II features an innovative PVC detection algorithm. Assert-IQ also highlights a leading PVC detection algorithm that offers the ability to capture consecutive events, including couplets and triplets, and advanced algorithms that reduce false detections for AF and Pause.